Abeona Therapeutics Inc. is a fully-integrated leader in gene and cell therapy, with a mission to develop and deliver life-changing therapies for people impacted by serious diseases. Their primary focus is on recessive dystrophic epidermolysis bullosa (RDEB) and other rare genetic conditions. Abeona has a portfolio of AAV-based gene therapies and an autologous cell therapy, supported by in-house cGMP manufacturing capabilities. The company is committed to scientific innovation and addressing significant unmet medical needs in the rare disease community.
The Cleveland headquarters serves as the central hub for Abeona's executive leadership, administrative operations, clinical development oversight, research strategy, and business development activities.
The headquarters is located in a modern office building within Cleveland's Health-Tech Corridor, designed to support the needs of a biopharmaceutical company. The focus is on functional, state-of-the-art office environments that foster innovation.
Abeona fosters a patient-centric and science-driven work culture. It emphasizes collaboration, innovation, integrity, and a strong commitment to developing transformative therapies for individuals affected by rare diseases.
Its Cleveland location provides Abeona with access to a rich talent pool, leading medical research institutions, and a supportive environment for biotechnology companies, crucial for its research and clinical development programs.
While Abeona Therapeutics' core operations, including its headquarters and cGMP manufacturing, are based in the United States (Cleveland, Ohio), its impact is global. The company conducts clinical trials that may involve international sites to reach diverse patient populations for rare diseases. Furthermore, Abeona has entered into strategic collaborations, such as the licensing agreement with Chiesi Global Rare Diseases for the commercialization of EB-101 (Pz-cel™) in Europe and other select markets, extending its therapeutic reach internationally pending regulatory approvals.
6555 Carnegie Ave, Suite 410
Cleveland
Ohio
USA
Address: Cleveland, Ohio (Specific street address for the cGMP facility is not consistently publicized for general public, but it is a distinct site from the corporate HQ)
The Cleveland-based GMP facility is integral to Abeona's research, development, and future commercialization efforts, enabling in-house manufacturing, quality control, and process development for its advanced therapy candidates. This ensures control over the supply chain for its specialized treatments.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Abeona Therapeutics' leadership includes:
Abeona Therapeutics has been backed by several prominent investors over the years, including:
Over the past 12-18 months, Abeona Therapeutics has significantly reshaped its executive leadership team. This includes the appointment of a permanent CEO (previously interim), a new CFO, a new CTO, and a new Head of R&D and CMO. These changes occurred alongside departures of the former CEO and CFO, reflecting a period of strategic transition and team building for the company's next phase of growth and potential commercialization.
Discover the tools Abeona Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Abeona Therapeutics commonly uses a standard corporate email format. The most frequently observed pattern is the first initial of the employee's first name followed by their last name, all before the '@' symbol and the company domain.
[first_initial][last]@abeonatherapeutics.com
Format
vseshadri@abeonatherapeutics.com
Example
80%
Success rate
Abeona Therapeutics / GlobeNewswire • May 24, 2024
Abeona Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved Pz-cel™ (beremagene geperpavec), its autologous, COL7A1 gene-corrected epidermal sheets, for treating wounds in patients six months or older with Recessive Dystrophic Epidermolysis Bullosa. This is a landmark approval for the RDEB community....more
Abeona Therapeutics / GlobeNewswire • May 10, 2024
Abeona Therapeutics provided its Q1 2024 financial results and an update on its Biologics License Application (BLA) for EB-101 (Pz-cel™), noting its preparedness for the PDUFA target action date of May 25, 2024, and potential commercial launch. The company discussed its financial position and ongoing programs....more
Abeona Therapeutics / GlobeNewswire • September 26, 2023
Abeona Therapeutics announced an exclusive license agreement with Chiesi Global Rare Diseases to commercialize EB-101 (Pz-cel™) for RDEB in the European Union, U.K., Switzerland, and other specified markets. Abeona received an upfront payment and is eligible for further milestone payments and royalties....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Abeona Therapeutics, are just a search away.